In its final agreement to purchase Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a commercial stage biopharmaceutical company committed to creating and marketing targeted therapies for patients of all ages with life-threatening diseases, Baker McKenzie is representing Servier, an independent international pharmaceutical group governed by a foundation, for about USD 2.5 billion.